GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 272,648 shares, a decrease of 15.2% from the January 29th total of 321,661 shares. Based on an average daily trading volume, of 124,907 shares, the short-interest ratio is currently 2.2 days. Approximately 15.0% of the company’s shares are short sold. Approximately 15.0% of the company’s shares are short sold. Based on an average daily trading volume, of 124,907 shares, the short-interest ratio is currently 2.2 days.

GeoVax Labs Trading Down 1.8%

GOVX traded down $0.03 during mid-day trading on Thursday, hitting $1.68. 88,392 shares of the stock were exchanged, compared to its average volume of 167,384. The firm’s fifty day moving average is $2.93 and its two-hundred day moving average is $9.88. GeoVax Labs has a 1-year low of $1.26 and a 1-year high of $47.13. The company has a market cap of $3.06 million, a PE ratio of -0.05 and a beta of 3.81.

Institutional Investors Weigh In On GeoVax Labs

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in GeoVax Labs in the 1st quarter valued at approximately $27,000. Hudson Bay Capital Management LP acquired a new stake in shares of GeoVax Labs in the third quarter valued at $47,000. HRT Financial LP acquired a new position in GeoVax Labs during the 4th quarter worth $31,000. Armistice Capital LLC acquired a new position in GeoVax Labs during the 3rd quarter worth $253,000. Finally, Renaissance Technologies LLC purchased a new stake in GeoVax Labs during the 4th quarter worth about $104,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on GOVX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $187.50.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.